Ar­cel­lx and Gilead seek to un­seat Leg­end and J&J with mul­ti­ple myelo­ma cell ther­a­py

SAN DIEGO — Gilead and Ar­cel­lx say their ex­per­i­men­tal mul­ti­ple myelo­ma cell ther­a­py an­i­to-cel could be a safer ri­val to field lead­ers Leg­end Biotech and John­son …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER